Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 33 min ago
PreprintCC BY-NC-NDmedRxiv

Revascularisation versus amputation for chronic limb-threatening ischaemia: a systematic review and meta-analysis of clinical outcomes and patient characteristics

  • J. L. Green1
  • H. Davies
  • D. A. Russell
  1. 1Leeds Vascular Institute
Read full textPDFDOICite

Abstract

BackgroundThe relative merits of infrainguinal bypass and primary major lower limb amputation (MLLA) for chronic limb-threatening ischaemia (CLTI) remain uncertain, and the baseline profiles of patients selected for each strategy are poorly described.

MethodsA systematic review and meta-analysis were undertaken in accordance with PRISMA 2020 and prospectively registered (PROSPERO: CRD42022356094). MEDLINE, Embase, CENTRAL, and CINAHL were searched from inception to March 2025. Prospective studies of adults with CLTI undergoing primary infrainguinal bypass or primary MLLA were eligible. Mortality, major adverse cardiovascular events (MACE) and subsequent amputation outcomes were synthesised using random-effects meta-analysis of proportions. Baseline comorbidity profiles were also extracted.

ResultsTwenty-seven studies involving 6,576 patients were included: 5,779 underwent infrainguinal bypass and 797 underwent MLLA. After bypass, pooled mortality was 3.7% at 30 days (95% CI 2.8%-4.9%, I{superscript 2} = 49.4%), 18.5% at 1 year (95% CI 15.6%-21.9%, I{superscript 2} = 62.3%), and 54.3% at 5 years (95% CI 50.5%-58.0%, I{superscript 2} = 0%). After MLLA, pooled mortality was 9.2% at 30 days (95% CI 4.1%-19.3%, I{superscript 2} = 73.5%), 28.5% at 1 year (95% CI 13.3%-51.0, I{superscript 2} = 70.8%), and 39.9% at 2 years (95% CI 0.3%-99.3, I{superscript 2} = 90.5%), although longer-term estimates were limited by sparse data and marked heterogeneity. Thirty-day MACE was 6.5% (95% CI 4.3%-9.7, I{superscript 2} = 63.5%) after bypass and 2.8% after MLLA (95% CI 0.1%-37.6%, I{superscript 2} = 0%). Early subsequent major amputation after bypass occurred in 3.9% of patients (95% CI 2.0%-7.7%, I{superscript 2} = 91.2%), rising to 16.2% at 1 year (95% CI 12.6%-20.5%, I{superscript 2} = 82.0%) and 33.3% at 3 years (95% CI 20.1%-49.8%, I{superscript 2} = 0%). Early re-amputation after MLLA occurred in 10.9% of patients (95% CI 4.5%-24.4%, I{superscript 2} = 40.3%). Baseline comorbidity burden was high in both groups, with substantial heterogeneity across studies.

ConclusionsCLTI carries a poor prognosis regardless of treatment strategy. Infrainguinal bypass is associated with lower early mortality and better early limb preservation than primary MLLA, but long-term survival remains poor and later limb failure is common. Primary MLLA is not a low-risk alternative. Better contemporary comparative evidence utilising modern causal inference approaches is needed to support individualised decision-making.

Related

  1. Catching Two Birds with One Stone: A Primary Open Revascularisation First Approach in a Case Report of Chronic Mesenteric Ischaemia.
    Nelson Oliveira, Manuel João Silva, Bruno Pereirinha
    EJVES vascular forumPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMC
  2. Retrograde access revascularization in chronic limb threatening ischaemia.
    Yujia Gao, Lorenzo Patrone, Neil Davies +6
    CVIR endovascularPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  3. P105 Sjögren’s syndrome with ANCA-positive multi-system vasculitis with limb-threatening ischaemia
    Nishita Padmanabhan, Amruth Karthik, Alex Joseph Chandy +1
    Rheumatology advances in practicePeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  4. Coronary revascularisation in people with multiple long-term conditions: a systematic review and meta-analysis
    A. Cheng, A. Alhashimi, C. J. Lim +5
    medRxivPreprintCC BYFull textCardiovascular medicinemedRxiv
  5. Targeted muscle reinnervation after traumatic or elective upper-extremity amputation: a systematic review and meta-analysis
    Fan-Long Meng, Ji-Ling Li, Xin Xue +5
    Frontiers in NeurologyPeer-reviewedCC BY 4.0Full textNeurologyCrossrefEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@misc{green2026revascularisation,
  title = {{Revascularisation versus amputation for chronic limb-threatening ischaemia: a systematic review and meta-analysis of clinical outcomes and patient characteristics}},
  author = {J. L. Green and H. Davies and D. A. Russell},
  howpublished = {medRxiv},
  year = {2026},
  month = aug,
  doi = {10.64898/2026.08.26.26361311},
  url = {https://www.medrxiv.org/content/10.64898/2026.08.26.26361311v1},
  note = {CC BY-NC-ND},
}
RIS
TY  - UNPB
TI  - Revascularisation versus amputation for chronic limb-threatening ischaemia: a systematic review and meta-analysis of clinical outcomes and patient characteristics
AU  - J. L. Green
AU  - H. Davies
AU  - D. A. Russell
PY  - 2026
DA  - 2026/08/26
PB  - medRxiv
DO  - 10.64898/2026.08.26.26361311
UR  - https://www.medrxiv.org/content/10.64898/2026.08.26.26361311v1
AB  - BackgroundThe relative merits of infrainguinal bypass and primary major lower limb amputation (MLLA) for chronic limb-threatening ischaemia (CLTI) remain uncertain, and the baseline profiles of patients selected for each strategy are poorly described.  MethodsA systematic review and meta-analysis were undertaken in accordance with PRISMA 2020 and prospectively registered (PROSPERO: CRD42022356094). MEDLINE, Embase, CENTRAL, and CINAHL were searched from inception to March 2025. Prospective studies of adults with CLTI undergoing primary infrainguinal bypass or primary MLLA were eligible. Mortality, major adverse cardiovascular events (MACE) and subsequent amputation outcomes were synthesised using random-effects meta-analysis of proportions. Baseline comorbidity profiles were also extracted.  ResultsTwenty-seven studies involving 6,576 patients were included: 5,779 underwent infrainguinal bypass and 797 underwent MLLA. After bypass, pooled mortality was 3.7% at 30 days (95% CI 2.8%-4.9%, I{superscript 2} = 49.4%), 18.5% at 1 year (95% CI 15.6%-21.9%, I{superscript 2} = 62.3%), and 54.3% at 5 years (95% CI 50.5%-58.0%, I{superscript 2} = 0%). After MLLA, pooled mortality was 9.2% at 30 days (95% CI 4.1%-19.3%, I{superscript 2} = 73.5%), 28.5% at 1 year (95% CI 13.3%-51.0, I{superscript 2} = 70.8%), and 39.9% at 2 years (95% CI 0.3%-99.3, I{superscript 2} = 90.5%), although longer-term estimates were limited by sparse data and marked heterogeneity. Thirty-day MACE was 6.5% (95% CI 4.3%-9.7, I{superscript 2} = 63.5%) after bypass and 2.8% after MLLA (95% CI 0.1%-37.6%, I{superscript 2} = 0%). Early subsequent major amputation after bypass occurred in 3.9% of patients (95% CI 2.0%-7.7%, I{superscript 2} = 91.2%), rising to 16.2% at 1 year (95% CI 12.6%-20.5%, I{superscript 2} = 82.0%) and 33.3% at 3 years (95% CI 20.1%-49.8%, I{superscript 2} = 0%). Early re-amputation after MLLA occurred in 10.9% of patients (95% CI 4.5%-24.4%, I{superscript 2} = 40.3%). Baseline comorbidity burden was high in both groups, with substantial heterogeneity across studies.  ConclusionsCLTI carries a poor prognosis regardless of treatment strategy. Infrainguinal bypass is associated with lower early mortality and better early limb preservation than primary MLLA, but long-term survival remains poor and later limb failure is common. Primary MLLA is not a low-risk alternative. Better contemporary comparative evidence utilising modern causal inference approaches is needed to support individualised decision-making.
ER  -